Feline Myasthenia Gravis

Feline myasthenia gravis (MG) is an acquired or congenital disorder of neuromuscular transmission in which failure of acetylcholine signaling at the neuromuscular junction (NMJ) results in episodic or persistent skeletal muscle weakness [1][5]. The acquired form—by far the more clinically common presentation in cats—is an autoimmune condition driven by circulating autoantibodies directed against nicotinic acetylcholine receptors (AChRs), leading to their functional depletion at the NMJ [6]. A rarer congenital form also exists and is caused by genetic defects affecting NMJ structure or function rather than autoimmunity [1]. Although MG is well-recognised in dogs, it occurs less frequently in cats, and the species differ in important clinical features including thymoma association rates and clinical phenotype [6].

Acquired Myasthenia Gravis (autoimmune): In the acquired form, the immune system generates IgG autoantibodies against the alpha-subunit of the nicotinic AChR located on the postsynaptic membrane of skeletal muscle NMJs [5][6]. These antibodies cause receptor loss through three mechanisms: (1) complement-mediated destruction of the postsynaptic membrane, (2) direct blockade of the receptor's acetylcholine-binding site, and (3) cross-linking and accelerated internalisation of AChRs [6]. The result is a reduced number of functional AChRs, so that normal acetylcholine release from the motor nerve terminal produces insufficient depolarisation of the muscle fibre, causing the characteristic fatigable weakness [5][6].

The trigger for autoimmunity in cats is not fully established, but thymoma—a thymic epithelial tumour—is an important associated condition. In cats, thymoma is considered a significant predisposing factor for acquired MG, with the thymus likely harbouring autoreactive T cells that drive the AChR-directed antibody response [6]. Thymoma-associated MG should therefore always be considered and excluded diagnostically.

Congenital Myasthenic Syndromes (CMS): Congenital forms are not autoimmune in origin but result from inherited genetic mutations affecting components of the NMJ, including presynaptic, synaptic basal lamina, or postsynaptic proteins [1]. These syndromes manifest from a young age and are not associated with circulating AChR antibodies [1][6]. The specific genetic mutations in affected cat populations are not as thoroughly characterised as in certain dog breeds.

Relationship to Other Conditions: In humans and dogs, MG may be paraneoplastic. In cats, the coexistence of thymoma and MG is well documented; successful thymoma resection has been associated with improvement or resolution of MG signs in some cases [6]. Hyperthyroidism, though clinically common in cats, does not directly cause MG but may complicate neuromuscular assessments [7].

Diagnosis of feline MG requires integration of clinical signs, pharmacological testing, serological testing, and electrophysiological studies.

1. Clinical Assessment: A thorough neurological and physical examination is essential. Hallmark findings include fatigable weakness, cervical ventroflexion, absent palpebral reflexes, regurgitation, and a history of exercise-exacerbated weakness [4][2]. These findings should prompt further NMJ-specific testing.

2. Anticholinesterase Challenge (Edrophonium / Neostigmine Test): Administration of a short-acting anticholinesterase drug—edrophonium chloride (Tensilon test) or neostigmine methylsulfate—temporarily inhibits acetylcholinesterase at the NMJ, increasing the concentration and duration of action of acetylcholine, transiently restoring neuromuscular transmission. A positive response (transient resolution of weakness) strongly supports MG [4]. Neostigmine methylsulfate has been evaluated as a diagnostic alternative; in a multi-institutional study including cats, the sensitivity and specificity of the neostigmine challenge were assessed relative to AChR antibody titres, with the test having practical diagnostic utility but also noted limitations [3]. Muscarinic side effects (salivation, bradycardia, defecation) may occur and atropine should be available [3][5].

3. Serum Acetylcholine Receptor Antibody Titre: Measurement of serum AChR antibody titre by radioimmunoassay is considered the definitive confirmatory test for acquired MG [5][6]. Positive titres confirm the autoimmune basis of the condition. All three acquired MG cats in the original case series by Joseph et al. tested positive for serum autoantibodies against feline AChRs [4]. It is important to note that a small proportion of patients may be seronegative despite having MG (seronegative MG), possibly involving antibodies to other NMJ targets.

4. Electromyography (EMG) and Repetitive Nerve Stimulation: Repetitive nerve stimulation studies can demonstrate a decremental response in compound muscle action potential amplitude, which is consistent with impaired NMJ transmission [5][6]. These electrophysiological studies support the diagnosis, particularly in seronegative cases.

5. Thoracic Imaging: Thoracic radiographs or computed tomography (CT) of the chest should be performed in all cats with confirmed or suspected MG to evaluate for megaoesophagus, thymoma, or aspiration pneumonia [5][6]. Thymoma appears as a cranial mediastinal mass on thoracic imaging.

6. Routine Laboratory Work: Standard clinicopathological testing is generally performed to exclude metabolic differentials and assess systemic health:

• ·Complete blood count (CBC): typically unremarkable in MG; anaemia or elevated white blood cell count (WBC) may suggest concurrent aspiration pneumonia or paraneoplastic effects
• ·Serum biochemistry: including albumin (ALB), globulin (GLOB), blood urea nitrogen (BUN), creatinine (CREA), alanine aminotransferase (ALT), and total bilirubin (TBIL); these are generally within normal limits but are important to establish baseline organ function prior to immunosuppressive therapy
• ·Haematocrit (HCT) / packed cell volume (PCV): monitored especially if concurrent illness is suspected
• ·Platelet count (PLT): baseline assessment prior to treatment
• ·Thyroid hormone (total T4): hyperthyroidism should be excluded as a confounding condition in middle-aged to older cats presenting with weakness [7]
• ·Serum electrolytes: hypokalaemia is an important differential cause of cervical ventroflexion in cats and must be excluded [2]
• ·Creatine kinase (CK): usually normal in MG (unlike primary myopathies)

7. Muscle and Nerve Biopsy: In atypical or congenital cases, muscle biopsy with histopathology and specialised immunohistochemical staining for NMJ components may be required to characterise CMS [1][6].

1. Anticholinesterase Therapy (First-Line Pharmacological Treatment): Oral pyridostigmine bromide is the mainstay pharmacological treatment for acquired MG. It reversibly inhibits acetylcholinesterase, prolonging the action of acetylcholine at the NMJ and thereby improving neuromuscular transmission [5][6]. Dosing must be titrated carefully in cats, as overdosage can cause a cholinergic crisis (excessive salivation, muscle fasciculations, bradycardia, increased bronchial secretions). The drug is administered orally two to three times daily, with the dose adjusted based on clinical response.

2. Immunosuppressive Therapy: Because acquired MG is autoimmune, immunosuppression is frequently employed to reduce autoantibody production [5][6]:

• ·Corticosteroids (e.g., prednisolone): used to suppress the autoimmune response. Paradoxically, steroid therapy can transiently worsen weakness early in the course of treatment, so initiation at a low dose with gradual escalation is recommended
• ·Azathioprine or mycophenolate mofetil: used as steroid-sparing agents in refractory or steroid-intolerant cases, though evidence in cats specifically is largely extrapolated from dogs and human medicine

3. Management of Megaoesophagus and Aspiration Risk: Megaoesophagus and regurgitation significantly increase the risk of aspiration pneumonia, a major cause of morbidity and mortality in MG patients [5][6]. Management strategies include:

• ·Feeding in an upright position (e.g., "Bailey chair" equivalent) and keeping the cat elevated for 10–15 minutes post-feeding
• ·Feeding semi-liquid or liquid food to minimise oesophageal retention
• ·Small, frequent meals
• ·Prompt treatment of aspiration pneumonia with appropriate antibiotics if present

4. Surgical Management of Thymoma: In cats with concurrent thymoma, surgical thymectomy is indicated both to address the neoplasm and because removal of the thymoma may lead to improvement or remission of MG [6]. Perioperative management requires careful anaesthetic planning, as neuromuscular blocking agents should be avoided or used with extreme caution.

5. Supportive and Intensive Care:

• ·Cats in respiratory distress may require oxygen supplementation, mechanical ventilation, or intensive monitoring
• ·Nutritional support via feeding tube may be necessary in severely affected or dysphagic patients
• ·Treatment of concurrent aspiration pneumonia with antibiotics

6. Congenital Myasthenic Syndromes: Pyridostigmine may be beneficial in some CMS subtypes, but the response depends on the specific underlying molecular defect [1]. Immunosuppression is not indicated for CMS, as it is not an autoimmune condition.

The prognosis for feline MG is variable and depends primarily on disease severity, presence of megaoesophagus, occurrence of aspiration pneumonia, and whether a concurrent thymoma is present.

Acquired MG: In general, cats with acquired MG have a guarded to fair prognosis [5][6]. Spontaneous remission of acquired MG is well-documented in dogs and has also been reported in cats, occurring as autoantibody titres decline over time [6]. However, cats with severe megaoesophagus are at high risk of aspiration pneumonia, which is a leading cause of death in MG patients [5][6]. Cats with thymoma-associated MG may achieve remission following successful thymoma resection.

Specific mortality rate data for feline MG are limited in the available literature. Shelton (2002) highlights that aspiration pneumonia is a primary cause of morbidity and mortality, and that early, accurate diagnosis and appropriate therapy is of utmost importance to a good clinical outcome [5]. The mini-review by Shelton (2016) similarly emphasises that outcomes differ between dogs and cats and that species-specific differences in clinical presentation affect prognosis [6].

In the multi-centre cervical ventroflexion study (n = 86 cats), MG was among the differential diagnoses investigated; treatment outcomes varied by underlying cause, reinforcing that the aetiology of ventroflexion strongly influences prognosis [2].

Congenital MG / CMS: Prognosis for CMS depends on the specific syndrome and its severity. Some affected kittens may fail to thrive or die early; others may stabilise or partially improve [1]. Detailed feline-specific survival statistics are not available in the current literature.

Data limitation: No peer-reviewed study in the references cited above provides a specific numerical survival rate or case-fatality percentage for feline MG as a standalone statistic. Prognosis statements are therefore derived from clinical expert opinion and case series descriptions within the cited literature.

There is currently no established method to prevent acquired feline MG, as the precise immunological trigger remains incompletely understood in most cases [6].

Practical Recommendations:

• ·Regular veterinary examinations: routine health screening, including thoracic imaging in older cats, may facilitate early detection of thymoma before MG develops as a paraneoplastic complication
• ·Early thymoma management: prompt surgical removal of identified thymomas may reduce the risk of developing thymoma-associated MG or may prevent its progression [6]
• ·Monitoring at-risk cats: cats with a history of immune-mediated conditions may warrant heightened surveillance for neuromuscular signs
• ·Genetic counselling for CMS: for congenital forms, breeding cats known to carry heritable NMJ defects should be discouraged; affected lines should be removed from breeding programmes [1]
• ·No vaccine exists for MG in any species, as the condition is autoimmune or genetic rather than infectious or parasitic